Physician profile
Xiaoping He
NPI 1922487941
$816.94
in general payments reported to CMS, 2019-2025
15 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.00 · 2023: $106 · 2024: $426 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703 · Education: $46.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.29 |
| Education | $46.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $189.55 | 2023-2025 | |
| Medtronic, INC. | $139.44 | 2024-2025 | Gi Genius, Endoflip |
| Madrigal Pharmaceuticals | $133.29 | 2024 | Rezdiffra |
| Janssen Biotech, INC. | $73.89 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.00 | 2021 | |
| Merck Sharp & Dohme LLC | $38.37 | 2024 | Dificid |
| Celltrion USA INC. | $33.12 | 2024 | Zymfentra |
| Takeda Pharmaceuticals U.S.A., INC. | $29.69 | 2024 | Eohilia |
| Celgene Corporation | $18.62 | 2023 | Zeposia |
| Pfizer INC. | $18.56 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $18.46 | 2025 | Dupixent |
| Amgen INC. | $16.82 | 2025 | Uplizna |
| Lilly USA, LLC | $15.11 | 2024 | Omvoh |
| Ardelyx, INC. | $12.96 | 2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $12.06 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoping He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.